Mercer Global Advisors’s ADMA Biologics ADMA Stock Holding History

Mercer Global Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$105K	Buy	+11,639	New	+$184K	﹤0.01%	3005
2024 Q1	–	Sell	-15,500	Closed	-$70K	–	1950
2023 Q4	$70K	Sell	15,500 -200	-1%	-$740	﹤0.01%	1936
2023 Q3	$56K	Buy	15,700 +700	+5%	+$2.69K	﹤0.01%	1890
2023 Q2	$55K	Hold	15,000	–	–	﹤0.01%	1866
2023 Q1	$50K	Hold	15,000	–	–	﹤0.01%	1868
2022 Q4	$58K	Hold	15,000	–	–	﹤0.01%	1854
2022 Q3	$36K	Hold	15,000	–	–	﹤0.01%	1784
2022 Q2	$30K	Buy	+15,000	New	+$29.5K	﹤0.01%	1786

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Mercer Global Advisors's ADMA Position: Q1 2026 in Review

Mercer Global Advisors opened a new position in ADMA Biologics (ADMA) in Q1 2026: 11,639 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #3005 among its holdings. This is a return to the name: Mercer Global Advisors previously reported a position in ADMA as recently as Q4 2023.

Mercer Global Advisors first reported a position in ADMA in Q2 2022 and has held it in 8 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

Mercer Global Advisors held 11,639 shares of ADMA Biologics worth $105K as of Q1 2026.
ADMA Biologics was a new Mercer Global Advisors position in Q1 2026.
ADMA Biologics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #3005 holding.
Mercer Global Advisors first reported a position in ADMA Biologics in Q2 2022 and has held it in 8 quarters since.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.